Build status - In Progress

Assessing Study Drug CFZ533 in Patients with Sj grens Syndrome (TWINSS)

Recruiting
18 years - 99 years
All
6 participants needed
1 Location

Brief description of study

Purpose of this study to find out if the study drug CFZ533, also referred to as iscalimab, is safe and can help others who have Sjögren’s Syndrome (SjS). SjS is an autoimmune disease in which the body’s defense system attacks moisture-producing glands, causing symptoms of extensive dryness (for example, dry eyes and dry mouth), but which may also involve many organ systems, chronic pain and profound fatigue.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research,Sj grens Syndrome,TWINSS
  • Age: 18 years - 99 years
  • Gender: All

Male or female patient ≥ 18 years of age Classification of Sjögren's Syndrome according to ACR/EULAR 2016 criteria

Updated on 04 Aug 2024. Study ID: 842571

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Race
Ethnicity
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center